demonstrated that ITK inhibition monotherapy with BMS-509744 suppressed T cell lymphoma both in vivo and in vitro by downregulating TCR signaling pathway, which is highly activated in malignant T cells38. This evidence concerns the gene ITK and T-cell non-Hodgkin lymphoma.